AstraZeneca shared the topline result from the placebo-controlled ... before AZ and its partner Merck were able to cross the ...

AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns ...

AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of ...

AstraZeneca raises its fiscal 2024 guidance for the second consecutive quarter. This upgrade comes despite ongoing legal ...

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...

AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...

(Reuters) -AstraZeneca shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu (trastuzumab deruxtecan) in March 2019 and datopotamab deruxtecan in July 2020, except ...

On the results front, AstraZeneca is among the heavyweight companies in the spotlight. However, the biggest share price moves were by the smaller stocks DCC and ConvaTec. Read more on today’s labour ...

Nov 5 (Reuters) - AstraZeneca (AZN.L), opens new tab shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be ...

AstraZeneca said it doesn’t comment on ... The shares closed down 8.4%, the steepest one-day decline since March 2020. That took the stock to its lowest since March. The probe has created ...